Denosumab biosimilar - Oncobiologics

Drug Profile

Denosumab biosimilar - Oncobiologics

Alternative Names: ONO4010; ONS-4010

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncobiologics
  • Class Antineoplastics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bone cancer; Bone disorders; Bone metastases; Breast cancer; Male osteoporosis; Malignant hypercalcaemia; Multiple myeloma; Non-small cell lung cancer; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 24 Oct 2016 Denosumab is still in preclinical trials in USA (SC, Injection)
  • 24 Oct 2016 Oncobiologics plans a phase I trial in USA in 2017 (Oncobiologics Form S-1, June 2016)
  • 01 Oct 2015 Preclinical trials in Bone cancer in USA (SC) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top